학술논문
KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Document Type
Abstract
Author
Source
In Blood 23 November 2021 138 Supplement 1:4830-4830
Subject
Language
ISSN
0006-4971